CLS secures commercial access to important fiber technology. Purchases parts of the German laser technology company Laser- und Medizin-Technologie

Clinical Laserthermia Systems (CLS) (publ), is buying parts of the German laser technology company Laser- und Medizin-Technologie GmbH (LMTB) and securing access to LMTB’s patents and unique expertise in microstructuring of laser fiber. CLS and LMTB previously jointly developed the technology that is the core of the CLS diffuser fiber. The company has now secured the production and delivery of fiber at substantially lower cost than before. CLS is also extending its collaboration with German fiber manufacturer Advanced Fiber Tools (AFT), which has agreed to develop the industrial process for manufacture of the diffuser fiber, which is very important to CLS, in AFT’s Mittweda production plant in Germany. The purchase consideration is EUR 300,000 in cash.

CLS develops and markets the TRANBERG®|Thermal Therapy System, as well as disposable materials and methods for heat-induced immunotherapy for safe and gentle treatment of cancerous tumors. CLS has been cooperating with the German laser technology company LMTB since 2010 with regard to development of the company’s diffuser fiber, which is a laser fiber that makes it possible to treat larger cancerous tumors. The manufacturing technique for the fiber is based, among else, on unique expertise in microstructuring, which is the formation of the structure that gives the light its unique diffusion.

LMTB was declared bankrupt in February of this year, due to inadequate profitability. When this occurred, CLS identified a commercially attractive opportunity, by means of acquisition, to secure the continued development and production of the diffuser fiber and reduce production costs. Jointly with AFT, the parties agreed a solution wherein CLS assumes the machinery required to make the fiber, patent rights and two key employees. At no charge, AFT will develop an industrial process for manufacture of the diffuser fiber and will provide premises for the newly formed CLS GmbH. AFT is also given the option to sell the diffuser fiber to its customers in exchange for a royalty to CLS, in areas where CLS does not operate.

 “We are enthusiastic about the purchase, which gives us control over production and reduces production costs by about 25 percent. We have also expanded our relationship with AFT, which gives us a good starting position as we move into a commercial phase, where the supply process must work in all aspects,” says CEO Lars-Erik Eriksson, CLS.

Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)702 – 90 33 00   E-mail: lee@clinicallaser.se

Clinical Laserthermia Systems AB (publ) develops and markets a safe, gentle, effective, and clinically documented therapy for treatment of solid cancer tumors. The product is based on immunostimulating interstitial laser thermotherapy (imILT). CLS is listed on Nasdaq First North under the stock symbol CLS B. Certified Adviser is Västra Hamnen Corporate Finance. More information is available on the Company's website www.clinicallaser.se